Skip to main content
. Author manuscript; available in PMC: 2013 Aug 19.
Published in final edited form as: Am J Psychiatry. 2008 Apr 1;165(8):1040–1047. doi: 10.1176/appi.ajp.2008.07071135

FIGURE 1.

FIGURE 1

Scores on Cognitive Domains for Patients With Schizophrenia During the First Arm of Crossover Treatment With Placebo and Two Doses of DMXB-A

a Significant differences from baseline for DMXB-A at both 75 mg b.i.d. (t=2.05, df=25, p=0.05) and 150 mg b.i.d. (t=2.26, df=25, p=0.03).

b Significant difference from baseline for DMXB-A, 75 mg b.i.d. (t=2.25, df=25, p=0.03); nearly significant difference for DMXB-A, 150 mg b.i.d.(t=1.93, df=25, p=0.07).

c Significant difference from baseline for placebo (t=2.18, df=25, p=0.04).